Interestingly, there was an increase in 126-D/v120-A env recombinants in the siRNA-treated second round infection (with virus from untreated first round) as compared to the recombinants detected in the siRNA-treated first round (compare 41% of bar 4 to 26% of bar 2, Figure 4B). The gene discussed is ERVW-1; the disease is infection.